Core Points - The stock of Wangshan Wangshui (02630.HK) closed at HKD 52.85, reflecting a decline of 20.05% [1] - On November 6, the company was listed on the Hong Kong Stock Exchange, closing at HKD 82.00, which represented an increase of 145.73% [1] - The total number of shares issued in this offering was 17,597,800, with 1,759,800 shares allocated for public sale in Hong Kong and 15,838,000 shares for international sale [1] - At the time of listing, the total number of shares issued by the company was 167,597,800 [1] - The final offer price for the shares was HKD 33.370, resulting in total proceeds of HKD 587.24 million, with a net amount of HKD 527.36 million after deducting estimated listing fees of HKD 59.88 million [1]

Group 1 - The stock of 旺山旺水-B (02630.HK) experienced a significant decline of over 22% in the afternoon trading session [1] - The stock reached an intraday low of 51.2 HKD, which is still 53% higher than its initial public offering (IPO) price [1] - As of the report, the stock was down 21.03%, trading at 52.2 HKD, with a transaction volume of 49.85 million HKD [1]

Core Viewpoint - 旺山旺水-B (02630) experienced a significant decline of over 22% in the afternoon trading session, with a low of 51.2 HKD, still 53% higher than its IPO price, indicating volatility in its stock performance [1] Company Overview - 旺山旺水 focuses on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has developed a diversified pipeline of 9 innovative products, with 2 in commercialization, 4 in clinical stages, and 3 in preclinical stages [1] - In addition to its innovative drug pipeline, the company is also involved in the generic drug sector, with 3 products either commercialized or nearing commercialization [1] - The two core products of the company are LV232 and TPN171 [1] Financial Performance - For the fiscal years 2023 and 2024, as well as the first four months of 2024 and 2025, the company reported revenues of 200 million RMB, 11.832 million RMB, 3.224 million RMB, and 12.958 million RMB, respectively [1] - In 2024, the company recorded a net loss of 21.8 million RMB, contrasting with a net profit of 6.427 million RMB in 2023, attributed to a decline in revenue [1]

Core Viewpoint - The stock of Wangshan Wangshui-B (02630) has experienced a significant decline of over 22%, with a low of 51.2 HKD, although it remains 53% higher than its IPO price [1] Company Overview - Wangshan Wangshui focuses on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has developed a diversified pipeline of nine innovative products, with two in commercialization, four in clinical stages, and three in preclinical stages [1] - The company also has a generic drug segment, with three products either commercialized or nearing commercialization [1] - The two core products of the company are LV232 and TPN171 [1] Financial Performance - In 2023, the company recorded a revenue of 200 million RMB, with subsequent revenues of 11.832 million RMB, 3.224 million RMB, and 12.958 million RMB for the first four months of 2024 and 2025 respectively [1] - The company reported a net loss of 218 million RMB for 2024, compared to a net profit of 6.427 million RMB in 2023, attributed to a decline in revenue [1]

Core Viewpoint - 旺山旺水 (02630.HK) experienced a significant drop of 19.39% in its stock price on the Hong Kong Stock Exchange after its debut, closing at 66.10 HKD, following an initial surge of 145.73% on its first day of trading, where it closed at 82.00 HKD [1] Summary by Relevant Sections - **Initial Public Offering (IPO) Details** - 旺山旺水 issued a total of 17,597,800 shares in its IPO, with 1,759,800 shares allocated for public offering in Hong Kong and 15,838,000 shares for international offering [1] - The final offer price for the shares was set at 33.370 HKD, resulting in total proceeds of 587.24 million HKD [1] - After deducting the estimated listing fees of 59.88 million HKD, the net proceeds amounted to 527.36 million HKD [1] - **Market Performance** - The stock's performance on its first trading day was notably strong, with a closing price of 82.00 HKD, reflecting a substantial increase of 145.73% from the offer price [1] - However, the subsequent trading day saw a sharp decline, with the stock closing at 66.10 HKD, marking a decrease of 19.39% [1]

Group 1 - The stock of 旺山旺水-B (02630.HK) experienced a significant drop of over 18% on its second day of trading after surging more than 145% on the previous trading day [2] - The current stock price is approximately double the IPO price of 33.37 HKD, indicating strong initial market interest [2] - As of the latest update, the stock is trading at 67.05 HKD with a transaction volume of 50.82 million HKD [2]

Core Viewpoint - 旺山旺水-B (02630) experienced a significant drop of over 18% on its second day of trading after a previous surge of over 145%, with the current stock price still approximately double its IPO price of 33.37 HKD [1] Company Overview - 旺山旺水 was established in 2013 and is a biopharmaceutical company focusing on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has developed a diversified pipeline of nine innovative products, with two in commercialization, four in clinical stages, and three in preclinical stages [1] - In addition to its innovative drug pipeline, the company is also involved in the generic drug sector, with three products either commercialized or nearing commercialization [1] - The company's two core products are LV232 and TPN171 [1] Financial Performance - For the fiscal years 2023 and 2024, as well as the first four months of 2024 and 2025, the company reported revenues of 200 million RMB, 11.832 million RMB, 3.224 million RMB, and 12.958 million RMB, respectively [1] - In 2024, the company recorded a net loss of 218 million RMB, compared to a net profit of 6.427 million RMB in 2023, with the fluctuation attributed to a decline in revenue [1]

Core Viewpoint - 旺山旺水-B (02630) experienced a significant drop of over 18% on its second day of trading after a previous surge of over 145%, with its current stock price still approximately double the IPO price of HKD 33.37 [1] Company Overview - 旺山旺水 was established in 2013 and is a biopharmaceutical company focusing on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has developed a diversified pipeline of 9 innovative products, with 2 in commercialization, 4 in clinical stages, and 3 in preclinical stages [1] - In addition to its innovative drug pipeline, the company is also involved in the generic drug sector, with 3 products either commercialized or nearing commercialization [1] - The company's two core products are LV232 and TPN171 [1] Financial Performance - For the fiscal year 2023, the company recorded a revenue of RMB 200 million, with subsequent revenues of RMB 11.832 million, RMB 3.224 million, and RMB 12.958 million for the first four months of 2024 [1] - The company reported a net loss of RMB 218 million for 2024, compared to a net profit of RMB 6.427 million in 2023, with the fluctuation attributed to a decline in revenue [1]

| HK + + = = B | | | | --- | --- | --- | | 02630 L2 ▼ | | | | 66 600 37 | 82.000 最高 82.000 最低 66 | | | 0.013% 总量 -18.78%-15 400 块子 | 8400股 金额 | 56. | | 总值 112.3亿 市盈 -49.19 市净 | 2.74 | Vm | | 分时 | 五日 日K 周K 月K 更多 | | | 均价:72.658 价格:66.600 -15.400 -18.78% | | | | 97.700 | 19.15% 卖1 66.950 | | | | 买1 66.550 分时成交 | 2 | | | 10:35 66.500 | | | | 10:35 66.5501 | | | | 10:35 66.600↑ | | | 87000 | 10:35 66.6501 | | | | 10:35 66.800↑ | | | | 10:36 67.000↑ | | | | 10:36 67.000 | | | | 10:36 67.050↑ | | | | 10:36 67.050 ...

Core Insights - Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. officially listed on the Hong Kong Stock Exchange, marking the fifth company from Suzhou Industrial Park to go public this year [1][2] - The company was established in 2013 and focuses on innovative small molecule drug development, particularly in the fields of neuropsychiatry, reproductive health, and viral infections [1] - Wangshan Wangshui has a comprehensive integrated system covering the entire drug development process, with two products in commercialization, four in clinical research, and three in preclinical research [1] Company Overview - Wangshan Wangshui's core products include LV232, a treatment for severe depression, and TPN171, a PDE5 inhibitor for erectile dysfunction [1][2] - LV232 is set to enter Phase II clinical trials in China in April 2025, with completion expected in the second half of 2026 [1] - TPN171 was approved in Uzbekistan in September 2022 and is expected to be approved in China by July 2025, with a market value of RMB 93 billion projected for 2024 [2] Market Context - The biopharmaceutical sector in Suzhou is experiencing growth, with 14 companies in the pipeline for listing on the Hong Kong Stock Exchange, and 5 already having completed regulatory filings [2] - Suzhou has a total of 71 listed companies, with 280 companies overall, including 226 on the domestic A-share market, ranking fifth nationwide [2]